GTC
Ghost Tree Capital Portfolio holdings
AUM
$276M
This Quarter Return
+8.82%
1 Year Return
+49.13%
3 Year Return
+198.45%
5 Year Return
+1,783.74%
10 Year Return
+9,775.89%
AUM
$296M
AUM Growth
+$296M
(-2.5%)
Cap. Flow
-$1.25M
Cap. Flow
% of AUM
-0.42%
Top 10 Holdings %
Top 10 Hldgs %
54.02%
Holding
58
New
16
Increased
14
Reduced
9
Closed
10
Top Buys
| 1 |
Ascendis Pharma
ASND
|
$10M |
| 2 |
Sarepta Therapeutics
SRPT
|
$9.13M |
| 3 |
Amicus Therapeutics
FOLD
|
$8.47M |
| 4 |
Mersana Therapeutics
MRSN
|
$7.91M |
| 5 |
Kura Oncology
KURA
|
$6.89M |
Top Sells
| 1 |
IMMU
Immunomedics Inc
IMMU
|
$20.4M |
| 2 |
MRTX
Mirati Therapeutics, Inc. Common Stock
MRTX
|
$15.8M |
| 3 |
MNTA
Momenta Pharmaceuticals, Inc.
MNTA
|
$12.8M |
| 4 |
TG Therapeutics
TGTX
|
$10.7M |
| 5 |
Axsome Therapeutics
AXSM
|
$8.23M |
Sector Composition
| 1 | Healthcare | 90.45% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
TRIL
1
DELISTED
Trillium Therapeutics Inc.
TRIL
| $27.7M | 8.01% | 1,950,000 +425,000 | +28% | +$6.04M |
|
|
2
Ascendis Pharma
ASND
$11.8B
| $20.1M | 5.8% | 130,000 +65,000 | +100% | +$10M |
|
|
3
Mersana Therapeutics
MRSN
$36.5M
| $19.6M | 5.65% | 1,050,000 +425,000 | +68% | +$7.91M |
|
4
Iovance Biotherapeutics
IOVA
$807M
| $18.9M | 5.47% | 575,000 -5,000 | -0.9% | -$165K |
|
5
Immunovant
IMVT
$2.56B
| $18.5M | 5.34% | 525,000 | – | – |
|
|
CNST
6
DELISTED
Constellation Pharmaceuticals, Inc.
CNST
| $14.7M | 4.25% | 725,000 +75,000 | +12% | +$1.52M |
|
7
Adverum Biotechnologies
ADVM
$64.6M
| $12M | 3.46% | 1,161,375 +261,375 | +29% | +$2.69M |
|
|
MRTX
8
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
| $9.96M | 2.88% | 60,000 -95,000 | -61% | -$15.8M |
|
9
Aldeyra Therapeutics
ALDX
$351M
| $9.26M | 2.68% | 1,250,000 +250,000 | +25% | +$1.85M |
|
10
Rocket Pharmaceuticals
RCKT
$354M
| $9.14M | 2.64% | 400,000 -250,000 | -38% | -$5.72M |
|
|
11
Sarepta Therapeutics
SRPT
$1.78B
| $9.13M | 2.64% | +65,000 | New | +$9.13M |
|
|
12
Amicus Therapeutics
FOLD
$2.34B
| $8.47M | 2.45% | +600,000 | New | +$8.47M |
|
13
Aurinia Pharmaceuticals
AUPH
$1.58B
| $8.1M | 2.34% | 550,000 | – | – |
|
14
Fate Therapeutics
FATE
$120M
| $7.99M | 2.31% | 200,000 +75,000 | +60% | +$3M |
|
|
SURF
15
DELISTED
Surface Oncology, Inc. Common Stock
SURF
| $6.9M | 1.99% | 1,000,000 +300,000 | +43% | +$2.07M |
|
|
16
Kura Oncology
KURA
$686M
| $6.89M | 1.99% | +225,000 | New | +$6.89M |
|
17
BioCryst Pharmaceuticals
BCRX
$1.74B
| $6.7M | 1.94% | 1,950,000 +50,000 | +3% | +$172K |
|
18
Syndax Pharmaceuticals
SNDX
$1.41B
| $6.27M | 1.81% | 425,000 +240,000 | +130% | +$3.54M |
|
19
Agios Pharmaceuticals
AGIO
$2.19B
| $6.13M | 1.77% | 175,000 +60,000 | +52% | +$2.1M |
|
|
ISEE
20
DELISTED
IVERIC bio, Inc. Common Stock
ISEE
| $5.64M | 1.63% | 1,000,000 +100,000 | +11% | +$564K |
|
|
21
TG Therapeutics
TGTX
$4.65B
| $5.35M | 1.55% | 200,000 -400,000 | -67% | -$10.7M |
|
|
VRNA
22
Verona Pharma
VRNA
$9.16B
| $5.03M | 1.45% | +805,556 | New | +$5.03M |
|
23
Immunic
IMUX
$80.9M
| $4.92M | 1.42% | +265,000 | New | +$4.92M |
|
24
Arvinas
ARVN
$568M
| $4.72M | 1.36% | 200,000 +80,000 | +67% | +$1.89M |
|
25
KalVista Pharmaceuticals
KALV
$678M
| $4.41M | 1.27% | 350,000 | – | – |
|